New heart zapping tech tested for stubborn AFib
NCT ID NCT05408754
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two new devices that use energy pulses to treat persistent atrial fibrillation (a type of irregular heartbeat). 89 adults who had not responded to medication received a heart ablation procedure. The goal was to see if the devices are safe and can stop abnormal heart rhythms for at least a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pulsed field ablation and pulsed field cryoablation systems (devices that use energy to destroy heart tissue causing abnormal rhythms)
What this could lead to
If successful, this could provide a safer, more effective way to treat persistent atrial fibrillation, potentially reducing the need for long-term medication.
What could go wrong
This is an early, first-in-human study with only 89 participants, so results may not apply to everyone. There are risks of procedure-related complications like bleeding or heart damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blackrock Health
Dublin, A94 E4X7, Ireland
-
McGill University Health Centre (MUHC), Montreal General Hospital (MGH)
Montreal, Quebec, H3G 1A4, Canada
-
Nemocnice Na Homolce
Prague, 150 30, Czechia
-
Onze-Lieve-Vrouwziekenhuis (OLV)
Aalst, B-9300, Belgium
-
St Antonius Ziekenhuis
Nieuwegein, 3435, Netherlands
-
St George'S University Hospital
London, SW17 0QT, United Kingdom